1. Biosimilars Expected to Take Toll on Amgen
Biosimilar competition to multiple drugs is expected to reduce Amgens sales by
nearly US$ 9 Billion during 2013-2020
IMARC Group has recently released a new study suggesting that biosimilars will
erode a significant portion of Amgens sales during 2013-2020. According to the
report entitled “Biosimilar/Follow-on Biologics Market Report & Forecast: A
Focus on the US (2011-2020)” four products from Amgen - Enbrel
(Ethanercept), Epogen (Epoetin Alfa), Neupogen (Filgrastim) and Neulasta
(Pegfilgrastim) are expected to face biosimilar competition during 2013-2020.
The study that has done a robust analysis on 21 biopharmaceuticals facing
biosimilar competition expects the combined sales of Amgens four drugs to
decline by US$ 9 Billion during 2011-2020.
IMARC’s new report entitled “Biosimilar/Follow-on Biologics Market Report &
Forecast: A Focus on the US (2011-2020)” provides an analytical and statistical
insight into the US biosimilar market. The study, that has been undertaken
using desk-based as well as qualitative primary research, provides and draws
upon analysis of six aspects of the US biosimilar market.
Key Aspects Analyzed:
Evaluating the Current Market Landscape of Biosimilars:
Identification of currently marketed biosimilars and their historical
performance
Identifying the reasons for the slow uptake of currently marketed
biosimilars
Analyzing historical data to formulate conclusions on the future growth
and market trends of biosimilar
Evaluating the Extent of Price, Sales and Volume Erosions Caused by
Biosimilars:
Analyzing historical time series data on price, volume and sales erosion
in the US & Europe

2. Analyzing previous models and assumptions on price and volume
erosion caused by biosimilars
Evaluating and comparing price and volume erosion created by
biosimilars vis-a-vis by small molecule generics
Evaluating and comparing price, volume and sales erosion by biosimilars
across various biological classes
Evaluating the Market Potential of Biosimilars Across Various Molecules:
Molecules Covered: Somatropin (Genotropin/Humatrope/Other HGH), Epoetin
Alfa (Epogen/Eprex), Filgrastim (Neupogen), Pegfilgrastim (Neulasta), Insulin
Lispro (Humalog), Insulin Glargine (Lantus), Insulin Detemir (Levemir),
Interferon Beta-1A (Avonex), Interferon Beta-1A (Rebif), Interferon Beta-1B
(Betaferon), Bevacizumab (Avastin), Trastuzumab (Herceptin), Rituximab
(Mabthera/Rituxan), Cetuximab (Erbitux), Etanercept (Enbrel), Infliximab
(Remicade), Adalimumab (Humira), Ranibizumab (Lucentis), Omalizumab
(Xolair) and Natalizumab (Tysabri).
Focus of the Analysis for Each Molecule:
Historical background and overview
Historical brand sales
Patent position
Competing products
Biosimilars in pipeline
Brand and biosimilar sales forecast
Evaluating the Sales of Biosimilars across Various Indications:
Indications Covered: Immunology & Inflammation, Diabetes, Oncology, Blood
Disorders and Growth Deficiency
Focus of the Analysis for Each Indication:
Historical brand sales
Brand and biosimilar sales forecasts
Indication wise breakup of molecules
Evaluating the Biosimilar Competitive Landscape:

3. Identifying branded biological manufacturers that expect the highest
amount of erosion from biosimilars
Identifying biosimilar manufacturers and their pipelines
To obtain the complete report, please contact:
Asia: apac@imarcgroup.com
Phone: +91-120-425-6531
Europe, Middle East & Africa: ema@imarcgroup.com
Phone: +44-702-409-7331
North & South America: america@imarcgroup.com
Phone: +1-631-791-1145
To know more please visit: http://www.imarcgroup.com/biosimilarfollow-on-biologics-
market-report-forecast-a-focus-on-the-us-2011-2020/
Keywords
Biosimilar market, biosimilar industry, biogenerics market, us biosimilar market, biosimilar
monoclonal antibodies , follow-on biologics market,